Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EPA has shown efficacy in treating certain cancers I believe.
Next chance for any good. News is Fridat's script no.s . If thay are below 7500, we can expect stock to continue downward drift. If by some miracle they are close to 8000, maybey we can start some gradual upswing in price. All we have for the next several months is script progress to give us any hope of living to see reduce it. It would be nice to see revenues exceed cost of sales.
Next chance for any good. News is Fridat's script no.s . If thay are below 7500, we can expect stock to continue downward drift. If by some miracle they are close to 8000, maybey we can start some gradual upswing in price. All we have for the next several months is script progress to give us any hope of living to see reduce it. It would be nice to see revenues exceed cost of sales.
I'm giving up. Everything with this stock is a day late and a dollar short. There is no bottom to this stock as long as I have owned it. I'd sell, but I'd get so little I might as well ride it to zero.
I have lost a lot of money in this stock because I believed they had found the best and safest medication since aspirin. As a matter of fact I still believe that. Since GIA much has gone wrong for us investors, but I do not fault the decision to GIA. Bottom line I believe our biggest hurdle has been the FDA. Maybe I'm simple minded but I believe pure EPA has many profound characteristics that will make it the drug of choice in fighting many diseases. So if we can just see it through to an early termination of reduce it because of its superior efficacy, we will prove that the market is not an efficient discounting mechanism. God bless us all.
Let me get some more help. I believe Vascepa is much better re CVEs than most people think, not because it reduces trig, which it does, but because of its impact on inflammation. I believe this is the true MOA of Vascepa which is overlooked and which makes this a multi- billion dollar drug, with many more applications than just high trig reduction.
Thanx, but I am still somewhat confused. Total events of 1612 is 20% of population in 5 or 6 years after start of clinical testing. I assume that is 5.2% per year. You say 15% efficacy of vascepa over placebo. But what if it is much better. We can't go to either 1612 or 967 if vascepa is dramatically better than placebo. It would be unconscionable. Also, the better V is the longer it will take to get to the 60 percent milestone of 967.
If V is 0% better than P, 484V+484P=968 in about 2 years after full enrollment.
If V is 20%better than P, 440 + 528=968 in about 2.5 years.
If V is 50% better than P, 387+ 581=968 in about 2.8 years.
And if V should be 75% better than P, 352 + 616 in about 3 years.
The better V is, the longer it will take to get to the targeted markers!
I need some help understanding the reduce it study. To prove reduce- it works wit a 90% probability it is said that X number of CV events must occur. My understanding is that X is something over 1000. But I ask, if results are very lopsided in favor of Vascepa, how long will the trial last? Let's posit that Vascepa has 100 events with 10 deaths and the placebo group has 400 events with 100 deaths. Will we wait for 500 more events to prove results to the 90 % probability level? And who makes the decision to stop the study early for the benefit of the placebo group and the general population?
Yesterday CEO of ALJJ bought 46000 at the opening and stock rose about 50% in the day. Where are our management purchases, or do they see more downside risk???
Just as I thought we were due for some good news, management found a way to screw the pooch.
I too look for early termination of reduce-it due to vascepa's efficacy.
Thanx. Do we suspect that our patents protect against prc-4016??
BASF is an approved supplier of V for Amerin. BASF HAS A SUBSIDIARY pronova testing it's own lipid drug prc-4016. How does this impact the out look for Amerin and vascepa?
Can we please stop attacking one another, and stay on point?
1,vascepa's major beneficial property is as an anti-inflammatory + 2, the medical community is beginning to realize that the cause of most major diseases including CVEs is inflammation = 3, vascepa will differentiate itself from the placebo group much earlier than most people expect, leading to an earlier conclusion to reduce it than most estimate. Inflammation is the real culprit not the level of TGs, though they are important.
Ajax133 you sound like a bright fellow who no longer has a vested interest in the progress of Amarin, so why get on this board and harass those that are still positive on the long term outlook for AMRN? What kind of satisfaction do you get from your I told you so attitude? The only thing worse than a bad loser is a bad winner.
If 7000 scripts/wk = $1.50/share, will 12,500scripts/wk in mid-July = $2.70 / share? And 22,000 scripts/ week at year end = $4.75 a share at year end!!!
That is a steep curve, what are the odds?
A lot of hand wringing and pessimism maybe justified except one thing, the f...ing FDA WANTS REDUCE IT, SO SOMETHING HAS TO GIVE DOESNT IT.?
What I can't figure out, is who benefits most from the obvious corruption at the FDA, BP, or the trial lawyers that sue BP for the deadly drugs recently approved by the FDA.
P.S. LOL, if it weren't so true and so sad.
Which one of these three women has the balls to overturn the opinion of her predecessor.??
Which one of these three women has the balls to overturn the opinion of her predecessor.??
All this chem talk gives me a headache. All I can deduce is that pure EPA is the best anti-inflammatory ever discovered, making it the aspirin of the future. Now all that is necessary is raising it in the medical consciousness so that it can generate sales. A large and under appreciated step in this is the co-promotion agreement with Kowa. In the very near future scripts will begin to grow meaningfully. I further believe that once sales reach a healthy level and docs see the benefits of both V and Livalo (both best in class) a more permanent arrangement will be made to the benefit of all shareholders.
Recent price action suggests nothing good come out of Friday's CC, in fact leaks may be negative so hold on. Despite gloomy near term prospect, I think the market is substantially under estimating value of Kowa deal.these two companies are feeling each other out, how ca each bring value to the other. I think it is W S that will be very surprised at success of this would be partnership and would not be surprised to see
Kowa take Amarin private before the end of Q1, 2015, with additional performance shares for achieving certain goals.
How or where can we see a copy of the certification that is done signed seal and delivered
Biobill or Jesse L. How much separation in CV. events do we need for reduce it to be declared a success ?
I'll ask again, what kind of separation must Amariin show between control group and V group to have reduce- it called a success and get the A labeling?
A very good analysis of Amarins situation. But what kind of mid-term results would satisfy?
Assume V group has 5 CV events, what would placebo group have to show in the same time period to give V a favorable outcome? 10 CV events in the placebo group. 15? 20? I assume FDA would want some sort of definitive result. But if the difference is large, how long can they wait before they are really negligent? I'm with you, believing in V efficacy just don't know how long we will have to wait for a " meaningful" separation in results.
When, if possible, might we get early r- it results, especially if significant?
The ISIS study sounds ominous for the future of V, or am I wrong in this
This stock never closes at HOD.
Help, how can I block ricardoga? He is driving me nuts.
I'm not very good at fortune making or fortune telling so take what I say with a grain of salt. Things are coming together for amrn and within 10 weeks a bidding war will start. The winner of that war will be the loser because they will pay way to much for the stock. The penalty for conspiring to keep the stock depressed. Karma is a wonderful thing.
Amazing,
No new posts worth reading on a big down day.
No prx support, no verbal support.
They plan on using corn oil which will raise the probability of CV events amount placebo group, guaranteeing success of study for combo.